Eli Lilly and Co. (NYSE:LLY) is currently the best performer in the S&P 500 (SP500), after the pharmaceutical announced that its oral weight loss therapy medicine successfully completed its Phase 3 trial, which would allow the pharma giant to move forward with regulatory submissions.
Although the company is down year-to-date, -6.8%, it is up 3.5% on Tuesday and rated 4.70 – “strong buy” – by Seeking Alpha Quant metrics.
Seeking Alpha’s Quant system is driven by powerful computer processing and SA’s special ‘Quantamental’ analysis. It awards grades to stocks based on collective value, growth, profitability, earnings per share revisions, and price momentum metrics.
The other five biggest pharmaceuticals are way behind. Here is how other big pharma companies are doing:
- Novartis (NVS) – Up 0.6% on Tuesday and up 29.4% YTD. SA Quant rating: 3.46
- Bristol-Myers Squibb Co. (BMY) – Up 0.2% on Tuesday so far; down 16.5% YTD. Seeking Alpha Quant rating: 3.12
- Pfizer (PFE) – Up 0.2% on Tuesday but down 5.1% YTD. SA Quant rating: 3.46
- Merck & Co. (MRK) – Flat on the day, down 14.2% YTD. SA Quant rating: 4.14
- Johnson & Johnson (JNJ) – Down 0.5% on Tuesday so far, but up 21.9% YTD. SA Quant rating: 3.48